Can immunotherapy before or after chemoradiation beat esophageal cancer?

NCT ID NCT07733830

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is investigating the best time to give immunotherapy for people with advanced esophageal cancer that cannot be removed by surgery. Participants will receive either immunotherapy before chemoradiation or after, to see which sequence helps control the cancer longer. The study aims to find a more precise treatment plan to potentially extend survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (an immunotherapy drug) combined with chemotherapy (nab-paclitaxel and carboplatin) and radiation therapy
What this could lead to: If successful, this could help determine the best timing for immunotherapy in treating advanced esophageal cancer, potentially improving survival.
What could go wrong: This is a phase 2 trial with a relatively small number of participants, so results may not be definitive. Immunotherapy and chemoradiation can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Hanan, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, Liaoning, China
National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China
Shanxi Cancer Hospital
RECRUITING

Taiyuan, Shanxi, China
Sichuan Cancer Hospital
RECRUITING

Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.